DynaGen licenses breast biopsy technology:
This article was originally published in Clinica
US company DynaGen has licensed BioLoc's technology for improving breast surgical biopsy procedures. The company says the technique overcomes problems with core needle biopsy procedures by guiding instruments directly to the suspected tissue lesion. Some eight million women in the US undergo breast screening annually. Of these, around 750,000 have surgical biopsies at a cost of $1,500 to $5,000 per treatment. The breast biopsy market is estimated at around $1,000 million.